{"url_path":"/sec/mcrb/8-k/2026-07-08/item-5","section_key":"item-5","section_title":"Item 5 Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Proposal 4.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":88,"has_tables":true,"body_markdown":"Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Proposal 4.\n\n \n\nVotes FOR\n  \nVotes AGAINST\n  \nVotes ABSTAINED\n  \nBroker Non-Votes\n\n3,299,526\n  \n741,254\n  \n75,681\n  \n868,715\n\n \n\nBased on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 5 were approved. Although Item 5 was approved, an adjournment of the Annual Meeting was not necessary because the Company’s stockholders approved Proposal 4."}